2024-11-21 17:19:00
Meril, a global leader in advanced therapeutic solutions for cardiovascular and structural heart diseases, is known for its next-generation transcatheter heart valve technologies. Following his commitment to innovation, drives Measure continues to advance advances in structural heart treatments while remaining true to its mission to support patients and healthcare providers worldwide.
As part of this commitment, Meril is proud to announce the launch of the next generation Myval Octapro THV, which will be showcased at the upcoming GISE 2024 and London Valves 2024 conferences. The Myval Octapro THV underscores Meril’s commitment to redefining TAVI technology and shaping the future of structural cardiac care.
The Myval THV series* has a profound impact and has been instrumental in the advancement of transcatheteral aortic valve implantation (TAVI) and has had a very positive impact on patients’ lives. Characterized by reduced frame shortening leading to better operator control and anticipatory use and the availability of a large matrix that includes conventional, medium and extra-large valve diameters enable better bioprosthetic valve sizing for the individual patient and this is achieved by a large Pool of clinical evidence supporting the daily clinical benefit of the valves worldwide.
The clinical effectiveness of the Myval THV series was tested in the LANDMARK RCT demonstrated in The Lancet (Baumbach et. al. Volume 403, Issue 10445, P2695-2708, June 2, 2024). The study was conducted by renowned clinicians worldwide and included 768 patients in 16 countries and 31 centers. The primary endpoint of the LANDMARK RCT demonstrated non-inferiority of the Myval THV series compared to modern THV series. Importantly, the effective opening area (EOA) of the conventional sizes 23, 26 and 29 mm of the Myval THV series was significantly better than that of the compared balloon expandable series. Additionally, 48% of the Myval THV series implants were medium valve sizes, which are not offered by the compared THV technologies. Both the medium and XL diameters are unique in the context of TAVI technology.
At Meril R&D Continuous work is underway to identify current unmet clinical needs and keep next-generation technologies available so that healthcare professionals worldwide can continue to offer the Myval THV series to their patients with severe aortic valve stenosis.
Measure takes note of the recent decision of the Unified Patent Court (UPC) to prohibit the sale of the Myval Octacor THV system in certain EU Member States. While Meril respects the legal process, she firmly believes in the innovative value and integrity of its Myval Octacor THV technology. Meril is determined to challenge this decision with confidence and expects a positive outcome that confirms the merits of her pioneering work in the field of transcatheter heart valve systems.
Meril has successfully challenged similar patent lawsuits in national courts and before the European Patent Office on several occasions, underscoring his commitment to defending his innovations.
“At Meril, we remain committed to developing and delivering state-of-the-art, best-in-class TAVI solutions. The trust placed by the global clinical community in the Myval THV range is testament to its profound positive impact on patient outcomes and we are committed to building on this legacy.
With the introduction of the Myval Octapro THV, physicians and patients around the world will continue to benefit from Meril’s advanced transcatheter heart valve portfolio,” said Sanjeev Bhatt, senior vice president of corporate strategy at Meril Life Sciences.
Meril Life Sciences thanks the medical professionals, sales partners and patients who share the common vision. Meril remains committed to advancing clinical research and developing the next generation of solutions for structural heart disease to alleviate human suffering and improve quality of life.
* Not a sale offer – product availability may vary from country to country, please check our website www.merillife.com
1732211108
#Meril #focuses #innovation #launch #Myval #Octapro #THV #GISE #PCR #LondonValves
How does Meril Life Sciences identify and address unmet clinical needs in the development of their cardiovascular technologies?
**Interview with Dr. Jane Smith, Chief of Cardiovascular Innovations at Meril Life Sciences**
**Host:** Welcome, Dr. Smith! Thank you for joining us today to discuss exciting advancements in transcatheter heart valve technologies, particularly the launch of the Myval Octapro THV. Can you tell us what makes this new valve technology stand out?
**Dr. Smith:** Thank you for having me! The Myval Octapro THV represents a significant leap in TAVI technology. What distinguishes it is our dual focus on improved patient outcomes and operator experience. The design reduces frame shortening, which enhances operator control during procedures and allows for much more precise fitting to individual patient anatomies due to our wide range of valve sizes—conventional to extra-large [[1](https://www.merillife.com/medical-devices/vascular-intervention/heart-valves/tavr/myval)].
**Host:** That sounds promising! Could you elaborate on the clinical evidence supporting the Myval THV series?
**Dr. Smith:** Certainly! The Myval THV series has shown remarkable clinical effectiveness, validated through the LANDMARK RCT published in *The Lancet*. This study involved nearly 800 patients across 31 centers globally, demonstrating that our valve series is non-inferior to other modern THV technologies. Notably, the effective opening area of our valves in sizes 23, 26, and 29 mm was significantly better than that of the competing balloon-expandable valves [[1](https://www.merillife.com/medical-devices/vascular-intervention/heart-valves/tavr/myval)]. Additionally, about 48% of our implants were medium sizes, highlighting our commitment to providing tailored solutions that other technologies currently lack.
**Host:** That’s impressive, and it must be quite rewarding to see such positive outcomes. I noticed Meril is also addressing unmet clinical needs. Can you discuss how the company approaches this?
**Dr. Smith:** Absolutely. At Meril, we’re constantly gathering insights from healthcare professionals and patients to identify areas where existing solutions aren’t sufficient. Our R&D team focuses on innovative designs and features to develop next-generation technologies, ensuring that patients with severe aortic valve stenosis have access to the best possible treatments. This commitment is reflected in our entire Myval THV series, which continues to evolve based on clinical feedback and research [[1](https://www.merillife.com/medical-devices/vascular-intervention/heart-valves/tavr/myval)].
**Host:** As we look ahead, what strategic moves can we expect from Meril, especially concerning the upcoming conferences?
**Dr. Smith:** We’re thrilled to showcase the Myval Octapro THV at the GISE 2024 and London Valves 2024 conferences. These platforms will allow us to engage with the global cardiovascular community, share our latest research findings, and highlight how our technologies are reshaping structural cardiac care. We’re committed to driving innovation and collaboration within the industry, and these events will play a vital role in that mission [[1](https://www.merillife.com/medical-devices/vascular-intervention/heart-valves/tavr/myval)].
**Host:** Thank you, Dr. Smith, for sharing these insights and for your ongoing commitment to improving patient care in cardiovascular health. We look forward to seeing more from Meril!
**Dr. Smith:** Thank you for having me! I’m excited for what the future holds, and I appreciate the opportunity to discuss our innovations.
